Stallergenes

Address: 6 Rue Alexis De Tocqueville

Sponsor Overview

assignment

Specializations

Allergic Rhinoconjunctivitis

Stallergenes focuses on birch pollen-induced allergic rhinoconjunctivitis, with clinical interest in the management of seasonal nasal and eye symptoms in children and adolescents.

Birch pollen allergy
Rhinoconjunctivitis symptom control
Pediatric allergy care

The sponsor’s research activity is centered on allergic disease affecting the upper airways and ocular tissues, with attention to symptom relief in young patients.

Respiratory Allergy

Its clinical research includes allergic airway disease linked to pollen exposure, reflecting interest in conditions that overlap with asthma in some patients.

Seasonal pollen allergy
Upper airway inflammation
Asthma comorbidity

This area highlights the sponsor’s involvement in respiratory allergy management across paediatric and adolescent populations.

Allergen Immunotherapy

Stallergenes is active in allergen immunotherapy for birch pollen sensitisation, with a therapeutic focus on reducing allergic symptoms and the need for rescue medication.

Birch pollen immunotherapy
Allergy symptom reduction
Rescue medication use

The sponsor’s trial portfolio reflects a specific interest in targeted treatment for pollen-driven allergic disease.

Paediatric and Adolescent Allergy

Clinical activity is directed toward paediatric and adolescent patients, with emphasis on allergic conditions that begin in early life and persist through school-age years.

Children aged 5 to 17 years
Adolescent allergy treatment
Seasonal symptom burden

This patient group is central to the sponsor’s therapeutic interest in age-specific allergy care.

Trial Name	Country	Status
Phase IIIb Double-Blind Placebo-Controlled Trial of Betula Pollen Extract in Pediatric Birch Pollen-Induced Allergic Rhinoconjunctivitis with or without Asthma	Austria Bulgaria Finland France Germany Hungary Latvia Lithuania Poland Romania Slovakia Sweden	Not Recruiting